Caplyta

Caplyta · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 12, 2028

~1.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (56)

Dec 10, 2040formulationUS 12122792
Dec 10, 2040formulationUS 12122792
Dec 10, 2040formulationUS 12122792
Dec 10, 2040formulationUS 12410195
Dec 10, 2040formulationUS 12410195
Dec 10, 2040formulationUS 12410195
Jul 7, 2040formulationUS 12090155
Oct 27, 2039method-of-use (U-3940)US 11980617
Oct 27, 2039method-of-use (U-3940)US 11980617
Oct 27, 2039method-of-use (U-3940)US 11980617
Aug 30, 2039formulationUS 10695345
Aug 30, 2039formulationUS 10695345
Aug 30, 2039formulationUS 10695345
Aug 30, 2039formulationUS 11052084
Aug 30, 2039formulationUS 11052084
Aug 30, 2039formulationUS 11690842
Aug 30, 2039formulationUS 11690842
Aug 30, 2039formulationUS 11690842
Aug 30, 2039formulationUS 11806348
Aug 30, 2039formulationUS 11806348
Aug 30, 2039formulationUS 11806348
Aug 30, 2039formulationUS 12070459
Aug 30, 2039formulationUS 12128043
Mar 15, 2039method-of-use (U-4261)US 12409176
Mar 15, 2039method-of-use (U-4261)US 12409176
Mar 15, 2039method-of-use (U-4261)US 12409176
Dec 3, 2034method-of-use (U-814)US 10960009
Dec 3, 2034method-of-use (U-3364)US 11026951
Dec 3, 2034method-of-use (U-3364)US 11026951
Dec 3, 2034method-of-use (U-3274)US 11026951
Dec 3, 2034method-of-use (U-2714)US 9956227
Dec 3, 2034method-of-use (U-2714)US 9956227
Dec 3, 2034method-of-use (U-2714)US 9956227
Aug 19, 2033method-of-use (U-814)US RE48839
Aug 19, 2033method-of-use (U-814)US RE48839
Aug 19, 2033method-of-use (U-3271)US RE48839
Dec 1, 2029compositionUS 86480773.4y
Dec 1, 2029compositionUS 86480773.4y
Dec 1, 2029compositionUS 86480773.4y
May 27, 2029method-of-use (U-3271)US 101178672.9y
May 27, 2029method-of-use (U-3271)US 101178672.9y
May 27, 2029method-of-use (U-3271)US 101178672.9y
May 27, 2029formulationUS 91682582.9y
May 27, 2029formulationUS 96160612.9y
May 27, 2029formulationUS 96160612.9y
May 27, 2029formulationUS 96160612.9y
Mar 12, 2029method-of-use (U-2713)US 91999952.7y
Mar 12, 2029method-of-use (U-4343)US 91999952.7y
Mar 12, 2029method-of-use (U-2713)US 91999952.7y
Mar 12, 2029compositionUS 95869602.7y
Mar 12, 2029compositionUS RE488252.7y
Mar 12, 2029compositionUS RE488252.7y
Mar 12, 2029compositionUS RE488252.7y
Mar 12, 2028formulationUS 104649381.7y
Mar 12, 2028formulationUS 104649381.7y
Mar 12, 2028formulationUS 104649381.7y

FDA exclusivities (3)

Nov 5, 2028I-904Indication (3y)2.3y
Nov 5, 2028I-904Indication (3y)2.3y
Nov 5, 2028I-904Indication (3y)2.3y

lumateperone tosylate

indications

all catalysts(7)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Patent cliff

patents (56)

FDA exclusivities (3)

Trials studying lumateperone tosylate